Automation has a long history of enhancing production, with the rise of automated machines in industries such as the automobile industry, as well as the pharmaceutical industry. However, the highly regulated biopharma sector has been slower to adopt fully automated technologies due to the complexity and variability of bioprocessing. Successful examples such as Moderna, which used automation and AI to develop an mRNA SARS-CoV-2 vaccine within a year, show that it is achievable without risking the quality and consistency crucial to therapeutic manufacturing. Despite the advantages of automation, there are potential challenges to consider, including implementation of fully automated systems can take time and changeover times depending on how flexible the systems are designed to handle changes and multiple products. The transition from paper-based or manual tracking to automated digital systems can be slow and met with resistance, but manufacturers can achieve remarkable success by consistently using technology to enhance processes and optimize human and capital resources.
Source
This post was brought to you by Wrk. Our bot looks for news related to automation and post daily.